Ipsen – Consolidated Financial Statements – 2022

Corporate 13 February 2025 6 mins read

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

Corporate 23 October 2024 4 mins read

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

Corporate 25 July 2024 7 mins read

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

Corporate 24 April 2024 7 mins read

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

Corporate 08 February 2024 8 mins read

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Corporate 26 October 2023 7 mins read

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

Corporate 27 July 2023 5 mins read

Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

Corporate 27 April 2023 9 mins read

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Corporate 09 February 2023 7 mins read

Ipsen presents strong full-year 2022 results and guidance for 2023

Corporate 28 July 2022 6 mins read

Ipsen delivers strong H1 2022 results and upgrades its full-year guidance